Clinical Trials
35 trialsTesting the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly and Company
SOFT
ETOP IBCSG Partners Foundation
TEXT
ETOP IBCSG Partners Foundation
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Alliance Foundation Trials, LLC.
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Thomas Jefferson University
The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Kisspeptin Administration in the Adult
Massachusetts General Hospital
Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
Medical University of South Carolina
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
M.D. Anderson Cancer Center
Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
Radiation Therapy Oncology Group
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
FASTR-2
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
Alliance for Clinical Trials in Oncology
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Aragon Pharmaceuticals, Inc.
Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists
Rabin Medical Center
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Radiation Therapy Oncology Group
MALE
GBG Forschungs GmbH
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
University of Washington
Neoadjuvant Endocrine Therapy in Breast Cancer
Guangdong Provincial People's Hospital
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
Radiation Therapy Oncology Group
POF
Peking Union Medical College Hospital
Co-SOFT
ETOP IBCSG Partners Foundation
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
Alliance for Clinical Trials in Oncology
Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
Memorial Sloan Kettering Cancer Center
Degarelix Neo-Adjuvant Radical Prostatectomy Trial
University Health Network, Toronto
AMH Levels Change During Treatment With GnRh Agonist
University Magna Graecia
Radiation Therapy in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Gonadotropin-releasing Hormone Agonist Prior to Myomectomy
Mt. Hope Maternity Hospital
A Study of Leuprolide to Treat Prostate Cancer
Abbott
Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids
University of Edinburgh